Share

Akeso Inc (9926.HKEX) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+92.1%

9926.HKEX does not currently pay dividends

1. Investment Thesis — Base Case

The central tension is that Akeso is two companies priced as one. The first is a reimbursed Chinese oncology franchise with twelve NRDL-listed indications, sales up 28.7% and a loss narrowing 26% [1] — a business converging on profitability whatever Washington decides. The second is a lottery ticket on the global PD-1xVEGF race, where four Phase III survival wins [3][4] compete against an interim PFS stumble [7] and three well-funded rivals [13][14][16]. Base case: the first company carries the valuation while the second decays from scarcity to one credible option among several.

TTM revenue US$832m at 12.7x sales; path assumes roughly 19% CAGR toward US$2bn by 2031.
First sustained GAAP profit around 2029; the projected HK$174 implies about 7x forward sales then.
RMB 9,160m liquidity funds burn to breakeven, keeping per-share dilution modest rather than punitive.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in HKD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (HKD)
Observed price	2021-09-14	43.7
Observed price	2021-10-04	40.0
Observed price	2021-10-08	41.0
Observed price	2021-10-24	47.3
Observed price	2021-11-05	39.2
Observed price	2021-11-21	51.1
Observed price	2021-11-25	50.2
Observed price	2021-12-15	38.5
Observed price	2021-12-19	35.4
Observed price	2022-01-08	28.4
Observed price	2022-01-12	29.9
Observed price	2022-01-28	20.3
Observed price	2022-02-13	18.89
Observed price	2022-02-17	20.4
Observed price	2022-03-01	21.8
Observed price	2022-03-13	15.00
Observed price	2022-03-25	17.72
Observed price	2022-04-14	15.42
Observed price	2022-04-30	14.57
Observed price	2022-05-08	12.11
Observed price	2022-05-12	12.20
Observed price	2022-06-01	16.62
Observed price	2022-06-05	16.88
Observed price	2022-06-25	25.2
Observed price	2022-07-07	26.1
Observed price	2022-07-19	22.4
Observed price	2022-08-04	20.9
Observed price	2022-08-08	22.9
Observed price	2022-08-20	21.4
Observed price	2022-09-01	25.9
Observed price	2022-09-13	25.9
Observed price	2022-09-25	20.8
Observed price	2022-10-03	22.1
Observed price	2022-10-23	30.1
Observed price	2022-11-04	29.9
Observed price	2022-11-16	34.0
Observed price	2022-12-06	31.1
Observed price	2022-12-10	40.7
Observed price	2022-12-18	40.9
Observed price	2023-01-03	47.3
Observed price	2023-01-07	46.0
Observed price	2023-01-27	51.0
Observed price	2023-02-04	47.6
Observed price	2023-02-16	42.4
Observed price	2023-03-12	39.5
Observed price	2023-03-16	45.5
Observed price	2023-04-01	40.1
Observed price	2023-04-09	45.1
Observed price	2023-04-13	46.6
Observed price	2023-04-25	41.1
Observed price	2023-05-07	44.7
Observed price	2023-05-27	35.0
Observed price	2023-06-08	34.3
Observed price	2023-06-16	37.5
Observed price	2023-06-24	33.8
Observed price	2023-07-14	37.1
Observed price	2023-07-30	41.7
Observed price	2023-08-07	32.9
Observed price	2023-08-23	31.3
Observed price	2023-08-31	34.5
Observed price	2023-09-08	35.1
Observed price	2023-09-16	37.9
Observed price	2023-10-06	35.2
Observed price	2023-10-14	38.8
Observed price	2023-10-22	38.4
Observed price	2023-11-07	47.9
Observed price	2023-11-19	46.2
Observed price	2023-12-01	48.5
Observed price	2023-12-09	43.4
Observed price	2023-12-29	46.4
Observed price	2024-01-10	48.1
Observed price	2024-01-22	40.9
Observed price	2024-02-03	39.6
Observed price	2024-02-15	42.1
Observed price	2024-02-19	44.0
Observed price	2024-03-10	47.5
Observed price	2024-03-18	51.9
Observed price	2024-04-03	45.6
Observed price	2024-04-19	43.9
Observed price	2024-04-27	48.8
Observed price	2024-05-09	50.5
Observed price	2024-05-21	47.2
Observed price	2024-05-29	31.8
Observed price	2024-06-02	44.0
Observed price	2024-06-26	40.3
Observed price	2024-07-04	36.5
Observed price	2024-07-16	39.3
Observed price	2024-08-01	42.2
Observed price	2024-08-05	41.8
Observed price	2024-08-25	46.4
Observed price	2024-08-29	48.3
Observed price	2024-09-18	68.1
Observed price	2024-09-22	63.8
Observed price	2024-10-04	74.4
Observed price	2024-10-16	65.9
Observed price	2024-11-05	69.3
Observed price	2024-11-17	65.5
Observed price	2024-11-25	76.8
Observed price	2024-12-03	70.7
Observed price	2024-12-23	60.0
Observed price	2024-12-31	60.6
Observed price	2025-01-12	55.6
Observed price	2025-02-05	59.1
Observed price	2025-02-09	64.7
Observed price	2025-02-13	56.0
Observed price	2025-03-05	73.5
Observed price	2025-03-25	65.8
Observed price	2025-03-29	75.1
Observed price	2025-04-06	70.0
Observed price	2025-04-22	88.4
Observed price	2025-04-26	95.0
Observed price	2025-05-12	79.5
Observed price	2025-06-01	77.9
Observed price	2025-06-09	87.3
Observed price	2025-06-29	92.1
Observed price	2025-07-03	106
Observed price	2025-07-07	113
Observed price	2025-07-27	150
Observed price	2025-08-04	152
Observed price	2025-08-16	168
Observed price	2025-08-24	172
Observed price	2025-09-13	133
Observed price	2025-09-17	129
Observed price	2025-10-07	142
Observed price	2025-10-11	128
Observed price	2025-10-31	113
Observed price	2025-11-04	111
Observed price	2025-11-12	118
Observed price	2025-12-06	124
Observed price	2025-12-18	116
Observed price	2025-12-30	111
Observed price	2026-01-07	129
Observed price	2026-01-15	122
Observed price	2026-02-04	103
Observed price	2026-02-08	101
Observed price	2026-02-20	109
Observed price	2026-03-04	95.3
Observed price	2026-03-24	120
Observed price	2026-03-28	129
Observed price	2026-04-17	151
Observed price	2026-04-21	147
Observed price	2026-05-03	130
Observed price	2026-05-15	120
Observed price	2026-06-04	99.5
Observed price	2026-06-08	92.3
Observed price	2026-06-16	84.7
Observed price	2026-07-06	102
Observed price	2026-07-18	90.0
Observed price	2026-08-03	91.8
Observed price	2026-08-11	102
Observed price	2026-08-23	89.0
Observed price	2026-09-04	101
Observed price	2026-09-16	90.4
Observed price	2026-09-21	99.3
Observed price	2026-09-25	93.5
Published advisor forecast	2026-09-18	90.5
Published advisor forecast	2026-12-18	96.8
Published advisor forecast	2027-03-18	106
Published advisor forecast	2027-06-18	100
Published advisor forecast	2027-09-18	108
Published advisor forecast	2027-12-18	114
Published advisor forecast	2028-03-18	121
Published advisor forecast	2028-06-18	116
Published advisor forecast	2028-09-18	124
Published advisor forecast	2028-12-18	130
Published advisor forecast	2029-03-18	135
Published advisor forecast	2029-06-18	131
Published advisor forecast	2029-09-18	139
Published advisor forecast	2029-12-18	146
Published advisor forecast	2030-03-18	152
Published advisor forecast	2030-06-18	156
Published advisor forecast	2030-09-18	150
Published advisor forecast	2030-12-18	158
Published advisor forecast	2031-03-18	164
Published advisor forecast	2031-06-18	169
Published advisor forecast	2031-09-18	174

2. Scenarios & Signals

Bull case

The bull case needs one bar cleared and one door opened. A clean HARMONi-3 final PFS and interim OS result restores first-mover primacy in first-line squamous NSCLC, which converts a narrow US label into a broad one and re-rates the Summit royalty stream from option to annuity. Compounding China volume then arrives against an easing rate regime, lifting both earnings and the multiple simultaneously. That combination supports a share price well above HK$250 by 2031.

Bear case

The bear case activates when the borderline becomes the verdict. A failed final HARMONi-3 PFS analysis followed by a restrictive or rejected US label strands royalty economics, while a rival prints a superior hazard ratio and multinationals localise aggressively in China. NRDL renewal then cuts price into decelerating volume, forcing continued negative free cash flow and an eventual placement. Valued on domestic product earnings alone, the shares would struggle to hold HK$55.

Current crowd narrative

The consensus trade treats ivonescimab as the anointed Keytruda successor: 23 analysts average Strong Buy with a HK$172 target, roughly 73% above the print [17][18]. Yet the shares fell 22% in thirty days and 24% in ninety [2]. That divergence is the tell — sell-side models remain anchored to the 2024 HARMONi-2 headline while price already discounts the HARMONi-3 interim stumble and a crowding bispecific field.

Alpha-gap assessment

The crowd underestimates these shares, though for unfashionable reasons. It prices one binary — HARMONi-3 and the FDA — and largely ignores the corroborated China engine: twelve NRDL-listed indications, H1-2026 sales of RMB 1,803.2m up 28.7%, a loss narrowing 26%, and RMB 9,160m of liquidity [1]. That is a self-funding franchise approaching breakeven without any US approval. The blind spot is treating royalty optionality as the whole valuation, when domestic earnings power alone supports most of today's price.

Convergence catalyst

Resolution of the HARMONi-3 final PFS analysis, guided for second-half 2026 [7], removes the binary overhang either way. The subsequent catalyst is FY2027 results showing an operating loss inside CNY 500m. First observable sign of repricing: analysts switching from price-to-sales to forward earnings multiples.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.1
Expected volatility regime: high_erratic
Convergence-cycle position: reversal

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Twelve Indications ONE Reimbursement MO	Follow the reimbursement trail: by end-2025 all twelve indications across five self-commercialised drugs sat inside China's National Reimbursement Drug List [1]. That converts growth from a pricing negotiation into a volume-and-indication problem, which is why H1-2026 commercial sales reached RMB 1,803.2m, up 28.7% year over year [1]. Price concessions are largely absorbed already, so incremental volume drops through a 78.7% gross margin, and the effect persists as new tumour types are added.	Not available	+45.0%
THE LOSS Curve IS Bending NOT Widening	The decisive number is not revenue but the gap: H1-2026 net loss narrowed roughly 26-27% to about CNY 418-424m while R&D grew only 5.6% year over year against 26% revenue growth [1]. Operating margin has improved from -160% in FY2022 to -30.8% in FY2025. Fixed clinical and commercial infrastructure now amortises across a larger sales base, which suggests operating leverage carries the company to breakeven without a step-change in spending.	Not available	+30.0%
FOUR Phase III WINS NOW ON Survival	The class's central doubt was whether progression-free benefit translates into survival. That doubt weakened materially: HARMONi-2's interim overall-survival analysis met its key secondary endpoint versus pembrolizumab [3], HARMONi-6 showed significant OS versus tislelizumab plus chemotherapy at an ASCO plenary [4], and HARMONi-GI1 hit in biliary tract cancer [2][5]. Each validated indication compounds addressable volume in China and strengthens Akeso's negotiating hand on downstream partnering economics.	Not available	+25.0%
Approval Cadence AS A Revenue Metronome	NMPA approval of ivonescimab plus chemotherapy in first-line squamous NSCLC [5] shows the regulatory machine working at pace, and the US HARMONi BLA was accepted with a November 2026 goal date, plausibly extended by a major amendment into early 2027 [11]. Each approval converts sunk clinical spend into recurring sales or Summit-linked milestone and royalty receipts. The cadence is the most predictable earnings escalator over the horizon.	Not available	+20.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
First Mover Premium Meets FOUR WAY RACE	Scarcity was the valuation argument, and it is evaporating. Merck's MK-2010 posted response rates similar to ivonescimab's 50% in HARMONi-2 [13], BMS/BioNTech's pumitamig reached 47% and entered a comprehensive global Phase III programme [16], and Pfizer's PF-08634404 is being pitted directly against Keytruda plus chemotherapy [14][15]. A crowded PD-1xVEGF field caps ex-China royalty rates and compresses the terminal multiple investors will pay, and this pressure only intensifies.	Not available	-30.0%
PEG Imports THE Fed's Tightening	A pre-profit franchise is a long-duration cash-flow claim, and the discount rate moved against it: the US 10-year closed at 4.998% on 18 September, the Fed range is 3.75%-4.00% with the median dot implying one further 2026 hike. The Hong Kong dollar peg transmits that directly into local funding costs and terminal-value arithmetic, irrespective of trial outcomes. The drag fades only when policy genuinely reverses.	Not available	-22.0%
R&d Hunger Versus FREE CASH FLOW	Cash generation remains the weak link in the evidence chain: FY2025 free cash flow was -CNY 1.83bn with capex at 23.9% of revenue, and TTM free cash flow is still -US$144m. RMB 9,160m of cash and short-term financial assets funds several years [1], but a global IO 2.0 ambition plus ADC, I&I and Alzheimer's programmes keeps reinvestment high. That defers per-share earnings and preserves a latent issuance overhang.	Not available	-18.0%
NRDL Renewal: THE Price Ratchet	Reimbursement is a two-edged instrument. The same listings that unlocked volume subject ivonescimab to periodic renewal negotiation, and gross margin has already slipped from 87.7% in FY2022 to 78.7% in FY2025 as mix shifted toward reimbursed product sales. Renewal rounds within the horizon will cut per-patient price, forcing volume to run harder simply to stand still. This is structural to the Chinese innovator model, not cyclical.	Not available	-15.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Harmoni 3 Clears THE Final BAR	The unresolved binary: after the independent board's interim PFS miss sent Summit down nearly 26% to $16.12 [7], the pre-planned final PFS and first interim OS analysis in first-line squamous NSCLC were guided for the second half of 2026 [7][9]. A clean win inside late 2026 or early 2027 would open the largest lung-cancer setting globally, re-rate Akeso's royalty and milestone stream, and restore the first-mover narrative. It stays below 50% because the interim result implies a borderline effect size.	38.0%	+55.0%
Second Molecule Second BIG Pharma Cheque	Akeso has proven it can monetise discovery through partnership, and management is now advancing bispecific ADC, immunology-and-inflammation and Alzheimer's assets [1]. A large upfront licensing deal on a non-ivonescimab asset, most plausibly between 2028 and 2030 after pivotal proof-of-concept data, would deliver non-dilutive cash, validate the platform beyond one target and force the market to value a pipeline rather than a single molecule. Probability stays modest because big pharma is currently concentrating oncology budgets on its own PD-1xVEGF programmes.	33.0%	+32.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Final PFS Misses FDA SAYS NO	The bear trigger is sequential: a failed final HARMONi-3 PFS analysis in late 2026 followed by a US complete response letter or a label restricted to the narrow post-TKI EGFR-mutant setting [11][12]. That would extinguish the ex-China royalty thesis, strand Summit-linked milestones and leave Akeso valued on China product sales alone — a defensible but far smaller business than 12.7x trailing sales implies. It remains below 50% because four separate Phase III regimens have already shown OS benefit [3][4].	34.0%	-38.0%
A Rival Prints A Better Hazard Ratio	Between 2028 and 2030, Pfizer/3SBio, Merck or BMS/BioNTech report head-to-head Phase III data superior to ivonescimab's [13][14][16]. Superiority elsewhere would reset both the royalty rate Akeso can command outside China and its domestic pricing power as multinationals localise, cutting long-run earnings and collapsing the scarcity premium. Probability is under 50% because ivonescimab holds a multi-year head start in enrolment and approvals, but the field is deep enough that one rival beating it is a live scenario.	29.0%	-30.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_51704e00-35e4-5099-b7e5-bb9241ef0a64__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (HKD)	Scenario rationale
1	December 18, 2026	+7.0%	96.84	HARMONi-3's final progression-free analysis and first interim survival read land inside this window, alongside a probably extended US decision date. Oversold positioning after a 24% drawdown plus the fresh HARMONi-2 survival win supports partial recovery.
2	March 18, 2027	+9.0%	105.55	US regulatory action arrives after the major-amendment extension. Even a narrow post-TKI label validates ex-China royalty mechanics and releases Summit-linked milestone cash, shifting the debate from binary survival to commercial execution and terminal value.
3	June 18, 2027	-5.0%	100.27	Classic sell-the-approval fade collides with NRDL renewal negotiations on ivonescimab indications, cutting per-patient price. Elevated US long yields transmitted through the Hong Kong dollar peg keep long-duration healthcare multiples under visible compression.
4	September 18, 2027	+8.0%	108.29	Interim results confirm volume growth outrunning reimbursement price cuts, with quarterly net loss narrowing toward CNY 300m. Investors start discounting a 2028-29 breakeven rather than pricing another dilutive financing round.
5	December 18, 2027	+5.0%	113.71	Biliary-tract and gastrointestinal label expansions begin converting into recorded revenue. Moderating US inflation trims policy-rate expectations, lifting Hong Kong risk appetite for growth healthcare names off depressed valuation multiples.
6	March 18, 2028	+6.0%	120.53	Full-year 2027 accounts show operating loss shrinking sharply on a high-seventies gross margin with R&D growth held below revenue growth. Explicit breakeven guidance attracts generalist institutional money previously absent.
7	June 18, 2028	-4.0%	115.71	Pfizer/3SBio and BMS/BioNTech pivotal readouts arrive. Broadly comparable efficacy commoditises the PD-1xVEGF class, trimming the royalty-rate premium and scarcity value embedded in Akeso's terminal assumptions.
8	September 18, 2028	+7.0%	123.81	Combination approvals broaden across Chinese tumour types while bispecific ADC and immunology assets enter registrational studies. Pipeline breadth, not a single molecule, starts carrying a meaningful share of the valuation.
9	December 18, 2028	+5.0%	130.00	A first quarterly operating profit becomes credible as cash burn approaches neutrality. The market begins anchoring on earnings rather than price-to-sales, a structurally higher-quality and more durable valuation basis.
10	March 18, 2029	+4.0%	135.20	Maiden annual profit is confirmed, but growth decelerates toward the high teens as core lung-cancer indications mature. Multiple normalisation offsets part of the positive earnings surprise this quarter.
11	June 18, 2029	-3.0%	131.14	Weak Chinese domestic demand and tightening provincial reimbursement budgets cap volume expansion. Competitive price discovery among second-generation checkpoint combinations pressures sentiment despite unchanged company fundamentals.
12	September 18, 2029	+6.0%	139.01	Ex-China royalty receipts scale as partner commercialisation broadens geographically. Royalty income arrives at near-total margin without incremental Akeso spending, lifting blended profitability faster than revenue growth alone suggests.
13	December 18, 2029	+5.0%	145.96	Next-wave assets deliver pivotal data and out-licensing discussions resume. Internally generated cash now funds the pipeline, dissolving the equity-issuance overhang that suppressed the multiple through the loss-making years.
14	March 18, 2030	+4.0%	151.80	Return on equity turns durably positive and earnings compound at a moderated pace. Valuation converges toward established Chinese innovator peers rather than speculative clinical-stage biotech comparables.
15	June 18, 2030	+3.0%	156.36	Steady execution with a thin catalyst calendar. Global oncology pricing-reform debate and US drug-pricing policy generate headline volatility but limited measurable impact on Akeso's China-weighted earnings.
16	September 18, 2030	-4.0%	150.10	Analysts begin modelling exclusivity decay and biosimilar-era pricing for the earliest antibodies. Slower second-half-decade growth assumptions trigger a modest but genuine valuation reset this quarter.
17	December 18, 2030	+5.0%	157.61	Fresh indication approvals and renegotiated international partnership economics restore growth visibility. Free cash flow conversion improves as the manufacturing capacity built in 2025-26 finally operates near full absorption.
18	March 18, 2031	+4.0%	163.91	Full-year results show a double-digit net margin. Capital-allocation signals — dividend initiation or continued repurchases against the 1.3% TTM net buyback yield — mark the transition to corporate maturity.
19	June 18, 2031	+3.0%	168.83	Incremental pipeline progression under a normalised rate regime. The shares now trade as a profitable specialty-pharma compounder, with returns tracking earnings growth rather than reflexive narrative swings.
20	September 18, 2031	+3.0%	173.89	Terminal-period drift. Mature franchise economics, mid-teens earnings growth and stable financing conditions deliver returns close to fundamental compounding, absent any fresh binary clinical or regulatory catalyst.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Superintelligence — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.